Verseau launches to develop first-in-class macrophage-targeted immunotherapies

Verseau Therapeutics has launched this week with $50 million in financing to develop first-in-class macrophage-targeted immunotherapies.

Funding came from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.

George Golumbeski, former Executive Vice President of Celgene, has been appointed Chairman of the Verseau Board of Directors.

The proceeds from the financing will support advancement of Verseau’s macrophage checkpoint modulator (MCM) programs to the clinic.

Macrophages can adopt different functional roles in response to signals from their environment, including the ability to direct pro-inflammatory and anti-inflammatory immune responses.

Verseau has licensed an siRNA delivery technology, a lipid nanoparticle, from the MIT laboratories of Verseau’s co-founders Dan Anderson and Bob Langer.

Verseau is using such delivery technologies as part of its all human translational system to discover and validate novel macrophage targets, creating an expansive pipeline of macrophage checkpoint modulators.

The lead program targeting PSGL-1 reprograms macrophages to a pro-inflammatory state, activates T-cells and attracts other immune cells to generate a coordinated and powerful antitumor response.

“Current immunotherapies can only provide clinical benefit in the 25% of cancers that involve T-cell infiltration. By targeting macrophages, present in 75% of human tumours, we believe we can offer potential clinical benefits of immunotherapy to a large, underserved patient population,” said Christine Bunt, CEO of Verseau.

“Macrophage modulation as monotherapy and in combination with other therapies could provide enhanced clinical benefit for patients.”

Tatiana Novobrantseva, co-founder and Chief Scientific Officer of Verseau, said: “Using our proprietary discovery and validation platform, we identified PSGL-1, an adhesion molecule that is highly expressed on tumour-associated macrophages across most tumour types, as the target of our first-in-class MCM program.

“Our PSGL-1 MCM antibody is designed to reprogram inhibitory tumour-associated macrophages into anti-cancer immune response stimulators. Verseau has validated more than two dozen targets amenable to different therapeutic modalities, including monoclonal antibodies.”

Verseau has a strategic collaboration with 3SBio. Under the agreement, 3SBio will receive an exclusive license to develop and commercialise a select number of MCM antibodies for all human oncology indications in Greater China. Verseau retains all global rights.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...